---
search:
  boost: 2 
---

# Gout

This is a subcategory of Analgesic Agents.

## Formulary

### Preferred

| Preferred      | Generic Name                    | Quantity                  | Time (Days)               |
|----------------|---------------------------------|---------------------------|---------------------------|
| Allopurinol QL | Allopurinol Tab (all strengths) | 204                       | 102                       |
| Colchicine Tab | Colchicine Tab (all strengths)  | Determined pursuant to PA | Determined pursuant to PA |
| Colcrys PA QL  | Colchicine Tab (all strengths)  | Determined pursuant to PA | Determined pursuant to PA |
| Probenecid QL  | Probenecid Tab (all strengths)  | 408                       | 102                       |

### Non-Preferred

| Non-Preferred            | Generic Name                                 | Quantity                  | Time (Days)               |
|--------------------------|----------------------------------------------|---------------------------|---------------------------|
| Mitigare BvG QL          | Colchicine Cap (all strengths)               | Determined pursuant to PA | Determined pursuant to PA |
| Febuxostat               |                                              |                           |                           |
| Gloperba Susp QL         | Colchicine Soln (all strengths)              | Determined pursuant to PA | Determined pursuant to PA |
| Probenecid/Colchicine QL | Probenecid w/ Colchicine Tab (all strengths) | Determined pursuant to PA | Determined pursuant to PA |

## Length of Authorizations

365 days except 180 days for Familial Mediterranean Fever

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Clinical PA Criteria:

-   Must have had an inadequate clinical response with an NSAID and oral corticosteroid within the last 30 days for acute gout diagnosis **OR**
-   Must have had an inadequate clinical response of at least 30 days with the maximally tolerated xanthine oxidase inhibitor dose for chronic gout diagnosis

## Non-Preferred Criteria

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least 30 days with at least one preferred drug
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Additional Criteria

### Colchicine Capsule (Mitigare)

Additional Colchicine Capsule (Mitigare) Criteria

-   Must have had an inadequate clinical response of 30 days with colchicine tablets

### Colchicine Solution (Gloperba)

Additional Colchicine Solution (Gloperba) Criteria

-   Must be unable to swallow tablets or capsules for authorization of colchicine solution

### Subsequent Authorization

Subsequent Authorization Criteria

-   Must provide documentation of patient’s clinical response to treatment and ongoing safety monitoring

**QL** – All colchicine products: 6 doses per claim for acute gout; 2 doses per day for 30 days for chronic gout; 4 doses per day per 30 days for Familial Mediterranean Fever

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=6)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=7)
